G-CSF Dosing Regimens
For chemotherapy-induced neutropenia prophylaxis, use filgrastim 5 µg/kg/day subcutaneously starting 1–3 days after chemotherapy until ANC reaches 2–3 × 10⁹/L, or pegfilgrastim 6 mg as a single subcutaneous injection 24–72 hours after chemotherapy—one dose per cycle. 1, 2
Filgrastim Dosing
Standard Chemotherapy Prophylaxis
- Dose: 5 µg/kg/day subcutaneously 1
- Timing: Begin 1–3 days (24–72 hours) after chemotherapy completion 1
- Critical restriction: Never administer within 24 hours before or during chemotherapy infusion, as this antagonizes cytotoxic effects 1
- Duration: Continue daily until ANC recovers to 2–3 × 10⁹/L 1
- Cycle coverage: Maintain prophylaxis through all chemotherapy cycles; limiting to first two cycles increases febrile neutropenia incidence from 10% to 36% 1
High-Dose Chemotherapy with Stem Cell Rescue
- Dose: 5 µg/kg/day subcutaneously 1
- Timing: May be initiated 1–5 days post-therapy 1
- Duration: Continue until ANC recovery is documented 1
Peripheral Blood Progenitor Cell Mobilization
- Dose: 10 µg/kg/day subcutaneously (higher than prophylaxis dose) 1
- Timing: Start four days before the first leukapheresis session 1
- Duration: Continue through the final leukapheresis procedure 1
Practical Dosing Example
- For a 50 kg patient: 5 µg/kg/day = 250 µg; use the 300 µg vial (6 µg/kg/day), which falls within the clinically effective 1–10 µg/kg/day range 1
- For a 70 kg patient: 5 µg/kg/day = 350 µg 1
Route of Administration
- Subcutaneous injection is the preferred route for all filgrastim indications 1, 3
- Intravenous bolus administration results in longer neutropenia duration (7.9 vs 5.4 days) compared to subcutaneous and should be avoided 4
Pegfilgrastim Dosing
Adults (≥45 kg)
- Dose: 6 mg as a single subcutaneous injection per chemotherapy cycle 2, 5
- Timing: Administer 24–72 hours (1–3 days) after chemotherapy completion 2, 5
- Critical restriction: Never give within 24 hours before or during chemotherapy 2
- Cycle coverage: Continue through all chemotherapy cycles; early discontinuation increases febrile neutropenia from 10% to 36% 2
Pediatric Patients
- Weight-based dosing: 100 µg/kg subcutaneously for patients <45 kg 5
- Fixed 6 mg dose contraindicated in children weighing <45 kg 2
- Pediatric dosing demonstrated in patients aged 0–21 years with sarcoma 5
Administration Options
- Next-day manual injection (preferred): 24–72 hours post-chemotherapy yields fastest neutrophil recovery 2
- On-body injector device: Applied on chemotherapy day, automatically delivers 6 mg approximately 27 hours later; pharmacokinetically equivalent to manual injection 2
- Same-day administration (use only when necessary): Reserve for patients unable to return for next-day dosing due to distance or immobility; produces earlier, deeper, longer neutropenia with markedly higher febrile neutropenia risk (OR ≈3.15 in breast cancer with high-risk regimens, OR ≈2.46 overall) 2
Lenograstim Dosing
- Specific activity: 127,760 IU/µg compared to filgrastim's 100,000 IU/µg 6
- Lenograstim demonstrates 25–30% higher blood stem cell mobilization (CD34+, CFU-GM) at mass-equivalent doses compared to filgrastim 6
- Dosing in international units (IU) rather than mass units (µg) is more appropriate given the potency difference 6
Comparative Effectiveness
Pegfilgrastim may be superior to filgrastim for reducing febrile neutropenia (relative risk 0.66; 95% CI 0.44–0.98), though all G-CSF agents (filgrastim, pegfilgrastim, tbo-filgrastim, filgrastim-sndz biosimilar) are acceptable 1
Selection should consider:
- Convenience: Pegfilgrastim requires one injection per cycle vs. daily filgrastim 1
- Adherence: Real-world data show patients often receive abbreviated filgrastim courses, reducing protection 7, 8
- Cost and clinical scenario 1
Indications for Prophylaxis
- Initiate when chemotherapy regimen carries ≥20% risk of febrile neutropenia 1, 9
- Consider patient risk factors (age ≥65 years, prior febrile neutropenia, low baseline neutrophil count) when regimen risk is 10–20% 9
- Support dose-dense or dose-intense chemotherapy with survival benefits 9
Contraindications and Special Populations
Pediatric Acute Leukemia
- Routine use NOT recommended in children with acute lymphoblastic leukemia (ALL) or non-relapsed acute myeloid leukemia (AML) without active infection 1
- Theoretical concern of stimulating leukemic blasts or stem cells 1
- In pediatric AML trials, filgrastim shortened neutropenia duration but did not reduce febrile neutropenia, documented infections, or infection-related mortality 1
- Five-year event-free survival comparable with or without G-CSF (58% vs 59%) 1
Other Contraindications
- Not indicated for infections unrelated to neutropenia (e.g., community-acquired pneumonia) 1
- Not indicated for primary treatment of aplastic anemia 1, 2
- Not indicated for therapeutic treatment of established febrile neutropenia (use empirical broad-spectrum antibiotics instead) 1
Safety Warnings
- Prolonged therapy carries theoretical but low absolute risk of secondary AML or myelodysplastic syndrome 1
- Monitor for splenic rupture, acute respiratory distress syndrome, allergic reactions, sickle cell crisis (in patients with sickle cell disease), glomerulonephritis, capillary leak syndrome, and aortitis 5, 3
Monitoring
- Obtain complete blood count with differential before starting G-CSF 1
- Monitor ANC every 2–3 days until target recovery (2–3 × 10⁹/L) is achieved 1
- Discontinue when ANC reaches target to avoid excessive leukocytosis 1
Common Pitfalls
- Premature discontinuation: Stopping prophylaxis after initial cycles markedly raises subsequent febrile neutropenia risk 1, 2
- Incorrect timing: Administering <24 hours after chemotherapy antagonizes cytotoxic effects 1, 2
- Wrong pediatric dose: Never use pegfilgrastim 6 mg fixed dose in children <45 kg 2
- Suboptimal daily G-CSF courses: Real-world practice shows abbreviated filgrastim courses reduce protection; pegfilgrastim once-per-cycle may improve adherence 9, 7, 8